Intervacc receives positive CVMP opinion for Strangvac, a vaccine against equine strangles, in the EU
Stockholm, June 17, 2021 - Intervacc AB (“Intervacc”) announced today that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Strangvac within the EU. Strangvac is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2021.
“We are very excited to receive a positive opinion from the CVMP. It is a long-awaited vaccine and an important step for the company as we move on to launch in the European market after approval.” said Andreas Andersson, CEO of Intervacc AB.
Emma Hartman, DVM and global product manager for the vaccine comments “This vaccine is a game-changer in our work to combat equine strangles by providing veterinarians with a valuable tool that can be used alongside current strategies to prevent outbreaks of this devastating disease. I am really delighted to continue the work on the launch of our vaccine.”
"Our vaccine is the first Swedish Animal Health vaccine to receive a positive opinion through the centralised procedure at the European Medicines Agency and it represents a milestone for a new generation of recombinant protein vaccines. We continue to work with the same technology to develop more vaccines to improve animal health, most notably against Staphylococcus aureus in cows and Streptococcus suis in pigs.”, stated Dr. Andrew Waller, Chief Scientific Officer at Intervacc
The vaccine has been developed with an innovative technology based on recombinant fusion proteins. The extensive research collaboration behind the vaccine’s technical platform has been achieved together with researchers at Karolinska Institute and the Swedish University of Agricultural Sciences, SLU. Strangvac, is injected intramuscularly and is totally devoid of any living infectious agent.
The process towards the approval of Strangvac for use in the UK is on-track and the company anticipates receiving a positive opinion before the end of July.
For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com
This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on June 17, 2021.
About Intervacc
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10
